2024-09-27 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for patients with life-threatening diseases.

**1. Performance Comparison:**

* **Cumulative Return:** GILD has underperformed the S&P 500 (VOO) by a significant margin. GILD's cumulative return is -14.39%, while VOO's is 133.29%. This translates to a cumulative return difference of -147.68%. This puts GILD at the 5.14% percentile of its historical performance relative to the S&P 500.

**2. Recent Price Action:**

* **Closing Price:** $82.21
* **5-day Moving Average:** $83.61
* **20-day Moving Average:** $81.45
* **60-day Moving Average:** $76.08

GILD's recent price action suggests a slight upward trend. The stock is currently trading above its 20-day and 60-day moving averages, but below its 5-day moving average.

**3. Technical Indicators:**

* **RSI:** 67.88 (Overbought territory)
* **PPO:** -0.16 (Weak momentum)
* **Delta_Previous_Relative_Divergence:** 0.54 (-) - Suggests a short-term downtrend.
* **Expected Return:** 0.0% (maximum 5-year expected return based on current investment)

The RSI indicates an overbought condition, while the PPO suggests weak momentum. The Delta_Previous_Relative_Divergence suggests a short-term downtrend. The expected return is currently 0%, which suggests limited upside potential.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

Gilead's most recent earnings report (2024-08-08) shows a beat on both EPS and revenue, with an EPS of $1.29 against an estimated $0.95. This strong performance shows continued revenue growth and a positive outlook for the company. 

**5. News and Recent Issues:**

**Recent Market Outlook:**
* **Analyst Opinions:** Gilead's stock has a mixed bag of ratings from analysts. While some analysts are bullish on the company's growth prospects, others are concerned about its long-term profitability and competition.
* **Performance Highlights:** Gilead has faced challenges in recent years, including declining sales of its flagship hepatitis C drugs. However, the company is diversifying its product portfolio and expanding into new areas, such as oncology and immunology.

**6. Overall Analysis:**

Gilead Sciences Inc. (GILD) has faced challenges in recent years, resulting in significantly lower returns compared to the broader market. The company is still facing headwinds, but recent earnings reports show potential for future growth. 

While the stock is currently trading above its long-term moving averages, technical indicators suggest a short-term downtrend. This could be an opportunity for investors to buy on the dip if they are confident in the company's long-term growth prospects. However, it's important to note the limited expected return and potential for future challenges.

**7. Key Takeaways:**

* Gilead Sciences Inc. has underperformed the S&P 500 significantly.
* Recent earnings reports show a positive trend and potential for future growth.
* Technical indicators suggest a short-term downtrend, but the stock is trading above its long-term moving averages.
* The expected return is limited, but there is potential for growth in the long term.

**Disclaimer:** This analysis is for informational purposes only and should not be considered as financial advice. 
